TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27776992

Group type: EXPERIMENTAL
Intervention: Sodium phosphate enema before urodynamics (group B)
Number of subjects: 139

Group type: COMPARATOR
Intervention: No enema before urodynamics (group A)
Number of subjects: 139
Study: 24231843

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin
Number of subjects: 250

Group type: COMPARATOR
Intervention: Combination of epirubicin and interferon-α2b
Number of subjects: 250
Study: 22402068

Group type: EXPERIMENTAL
Intervention: HAART with dietary intervention (diet group, n = 43)
Number of subjects: 83

Group type: COMPARATOR
Intervention: HAART without dietary intervention (control group, n = 40)
Number of subjects: 83
Study: 19955052

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 315
Study: 18663625

Group type: EXPERIMENTAL
Intervention: Obese patients
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group (N=165)
Number of subjects: 163
Study: 16190942

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (1 mg/day)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 12772233

Group type: EXPERIMENTAL
Intervention: 9 mm length NIR stent in small vessel
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 16 mm length NIR stent in small vessel
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 9 mm length NIR stent in large vessel
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 16 mm length NIR stent in large vessel
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 94
Study: 10870870

Group type: EXPERIMENTAL
Intervention: Quetiapine 600 mg/day
Number of subjects: 288

Group type: COMPARATOR
Intervention: Haloperidol 20 mg/day
Number of subjects: 288
Study: 9183341

Group type: EXPERIMENTAL
Intervention: Fasting insulin measurement
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Post-glucose insulin measurement
Number of subjects: 888
Study: 1581369

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 69

Group type: COMPARATOR
Intervention: Sham ultrasound
Number of subjects: 69
Study: 3853254

Group type: EXPERIMENTAL
Intervention: Preventive nursing intervention focusing on assessment of health history, health behaviors, health beliefs, education about CHD risk factors, and methods for detecting and reducing these factors.
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group received mailed questionnaires and no intervention.
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Preventive nursing intervention
Number of subjects: 58
Study: 30861208

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 87

Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 87
Study: 29778331

Group type: EXPERIMENTAL
Intervention: Goal-directed perfusion (GDP) strategy during cardiopulmonary bypass (CPB) aimed to maintain oxygen delivery (DO2) at ≥280 mL·min‐1·m‐2
Number of subjects: 350

Group type: COMPARATOR
Intervention: Conventional perfusion based on body surface area and temperature
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Goal-directed perfusion (GDP) strategy during cardiopulmonary bypass (CPB) for patients with CPB time between 1 and 3 hours
Number of subjects: 350
Study: 27260150

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg on day 1, 75 mg on days 2 and 3)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 25471907

Group type: EXPERIMENTAL
Intervention: Topical intra-articular TXA (3 g of TXA in 100 mL of physiological saline solution)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Intravenous TXA (15 mg/kg in 100 mL of physiological saline solution, one dose before tourniquet release and another three hours after surgery)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Topical intra-articular TXA
Number of subjects: 78

Group type: COMPARATOR
Intervention: Intravenous TXA
Number of subjects: 78
Study: 21999138

Group type: EXPERIMENTAL
Intervention: Single-session two-needle arthrocentesis (A)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Single-session two-needle arthrocentesis plus corticosteroid (B)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Single-session two-needle arthrocentesis plus low molecular weight hyaluronic acid (HA) (C)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Single-session two-needle arthrocentesis plus high molecular weight HA (D)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 5 weekly two-needle arthrocenteses plus low molecular weight HA (E)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 5 weekly single-needle arthrocenteses plus low molecular weight HA (F)
Number of subjects: 72
Study: 20042927

Group type: EXPERIMENTAL
Intervention: Static stretching (SS)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dynamic stretching (DS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No stretching (NS)
Number of subjects: 12
Study: 18388888

Group type: EXPERIMENTAL
Intervention: Diet and exercise (treatment group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 24
Study: 15538395

Group type: EXPERIMENTAL
Intervention: Alprostadil transdermal cream (approximately 100 mg containing 300 microg alprostadil) administered by self-insertion into the glans meatus.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Alprostadil transdermal cream (approximately 100 mg containing 300 microg alprostadil) administered dropwise into the metal opening without touching the penis.
Number of subjects: 7
Study: 12874157

Group type: EXPERIMENTAL
Intervention: 200 mg Chlorella-derived dietary supplement
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 400 mg Chlorella-derived dietary supplement
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 10563544

Group type: EXPERIMENTAL
Intervention: Nicotine solution (1.2 mg, pH 4.5)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 17
Study: 8671273

Group type: EXPERIMENTAL
Intervention: Laser-assisted hatching (group A)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Laser-assisted hatching (group B)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control group A' (intact zona pellucida)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control group B' (intact zona pellucida)
Number of subjects: 207
Study: 1681215

Group type: EXPERIMENTAL
Intervention: PCR‐EIA
Number of subjects: 234

Group type: COMPARATOR
Intervention: DFA
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Ocular tetracycline treatment
Number of subjects: 234
Study: 6496995

Group type: EXPERIMENTAL
Intervention: Epidural morphine (5.0 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous morphine (0.05-0.07 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Epidural morphine and Intravenous morphine
Number of subjects: 30
Study: 31614596

Group type: EXPERIMENTAL
Intervention: Digital support system for homework delivery via the Internet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional homework condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both conditions (Digital support system and Traditional homework)
Number of subjects: 0
Study: 30152782

Group type: EXPERIMENTAL
Intervention: Kinesiology Taping muscle application (KT group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo application of adhesive tape (placebo group)
Number of subjects: 50
Study: 26739116

Group type: EXPERIMENTAL
Intervention: Intermittent high‐intensity exercise (IHE)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (CONT)
Number of subjects: 10
Study: 24487957

Group type: EXPERIMENTAL
Intervention: High-intensity laser therapy (HILT) + exercise
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) + exercise
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo laser + exercise (PL + EX)
Number of subjects: 53
Study: 22204948

Group type: EXPERIMENTAL
Intervention: Multimedia program (Play Nicely) - 40-min lecture
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 19
Study: 20683071

Group type: EXPERIMENTAL
Intervention: Lidocaine nasal spray
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 206
Study: 22065170

Group type: EXPERIMENTAL
Intervention: Tovaxin (autologous T-cell immunotherapy)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 15976241

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 54

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 54
Study: 12850395

Group type: EXPERIMENTAL
Intervention: lercanidipine 10 to 20 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: nifedipine GITS 30 to 60 mg
Number of subjects: 60
Study: 10593371

Group type: EXPERIMENTAL
Intervention: 0.25 mg of ganirelix administered subcutaneously
Number of subjects: 19

Group type: COMPARATOR
Intervention: 0.25 mg of ganirelix administered intravenously
Number of subjects: 19
Study: 8915229

Group type: EXPERIMENTAL
Intervention: Dobutamine-atropine echocardiography
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Dipyridamole echocardiography
Number of subjects: 102

Group type: COMPARATOR
Intervention: Exercise stress test
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Dipyridamole and dobutamine-atropine echocardiography
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Dipyridamole infusion
Number of subjects: 102
Study: 1845584

Group type: EXPERIMENTAL
Intervention: Simple Advice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brief Counselling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extended Counselling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 6809161

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine chewing-gum
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (1 mg nicotine, unbuffered)
Number of subjects: 58
Study: 29195739

Group type: EXPERIMENTAL
Intervention: 3D laparoscopic gastrectomy
Number of subjects: 419

Group type: COMPARATOR
Intervention: 2D laparoscopic gastrectomy
Number of subjects: 419
Study: 28931384

Group type: EXPERIMENTAL
Intervention: Internet-based tool for parents (monthly emails with links to an age-appropriate website)
Number of subjects: 718

Group type: COMPARATOR
Intervention: Ordinary care from child health centres
Number of subjects: 718
Study: 26037730

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for 8 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Waiting list group (no acupuncture treatment)
Number of subjects: 39
Study: 23833851

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg) added to bupivacaine (0.5%) - fentanyl (50 microg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Bupivacaine (0.5%) - fentanyl (50 microg) with saline normal (control)
Number of subjects: 72
Study: 19961932

Group type: COMPARATOR
Intervention: Proguanil alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Proguanil with efavirenz (400mg daily for 11 days)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Proguanil with efavirenz
Number of subjects: 15
Study: 19213336

Group type: EXPERIMENTAL
Intervention: Kuntai Capsule (KTC) 4 capsules twice a day for 1 year
Number of subjects: 104

Group type: COMPARATOR
Intervention: Premarin 0.45 mg per day (with 2 mg medroxyprogesterone for Ue) for 1 year
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Kuntai Capsule (KTC)
Number of subjects: 104
Study: 16903931

Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg
Number of subjects: 778

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 778
Study: 12533086

Group type: EXPERIMENTAL
Intervention: Initial serum neuron-specific enolase (NSE) level
Number of subjects: 81
Study: 10812283

Group type: EXPERIMENTAL
Intervention: Daily buprenorphine administration (8 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thrice-weekly buprenorphine administration (16 mg on Mondays and Wednesdays, 24 mg on Fridays)
Number of subjects: 60
Study: 8652330

Group type: EXPERIMENTAL
Intervention: Mouthpiece breathing in supine position
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Mask breathing in supine position
Number of subjects: 13
Study: 2052294

Group type: EXPERIMENTAL
Intervention: 4-mm small incision with 6.5-mm silicone optic PC IOL
Number of subjects: 130

Group type: COMPARATOR
Intervention: 6.5-mm conventional incision with 6.0-mm PMMA optic PC IOL
Number of subjects: 130
Study: 6809024

Group type: EXPERIMENTAL
Intervention: Pirprofen 200 mg 8 hourly
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29384321

Group type: EXPERIMENTAL
Intervention: Astaxanthin (8 mg once daily for 8 weeks)
Number of subjects: 44
Study: 26922656

Group type: EXPERIMENTAL
Intervention: AZD8529 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risperidone 4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24126097

Group type: EXPERIMENTAL
Intervention: Eltrombopag (25-100 mg/day) for 9 weeks or fewer
Number of subjects: 1520

Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 1520

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1520
Study: 22889038

Group type: EXPERIMENTAL
Intervention: Next-day class scheduled at 8:30 a.m., 10:00 a.m., or 12:30 p.m. (academic constraint conditions)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Next-day class scheduled at 8:30 a.m. or 12:30 p.m. (academic constraint conditions)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: 8:30 a.m. exam condition
Number of subjects: 230

Group type: COMPARATOR
Intervention: No next-day class (control condition)
Number of subjects: 230
Study: 21076372

Group type: EXPERIMENTAL
Intervention: Valganciclovir prophylaxis (900 mg once daily for 200 days)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Valganciclovir prophylaxis (900 mg once daily for 100 days)
Number of subjects: 318
Study: 18179317

Group type: EXPERIMENTAL
Intervention: Effort to modulate the use of racial information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Less effort to modulate the use of racial information
Number of subjects: 0
Study: 16120821

Group type: COMPARATOR
Intervention: 32 mg/d candesartan
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 64 mg/d candesartan
Number of subjects: 32
Study: 11865366

Group type: EXPERIMENTAL
Intervention: High dose intravenous antithrombin III
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intraabdominal donor serum
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 36
Study: 10599402

Group type: EXPERIMENTAL
Intervention: Normovolemic haemodilution with crystalloid solutions until a hematocrit value of 21%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group with target transfusion hematocrit value of >= 28%
Number of subjects: 60
Study: 7783015

Group type: EXPERIMENTAL
Intervention: O‐ring attachment
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Magnet attachment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conventional denture
Number of subjects: 17
Study: 2396264

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 492050

Group type: EXPERIMENTAL
Intervention: Propranolol (0.1 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metoprolol (0.2 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Orciprenaline (7 micrograms/kg)
Number of subjects: 10
Study: 31779696

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2g/day for 26 weeks
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 27697423

Group type: EXPERIMENTAL
Intervention: Sticker prompts affixed to refuse bins in treatment group
Number of subjects: 33684

Group type: COMPARATOR
Intervention: Control group (no sticker prompts)
Number of subjects: 33684
Study: 25889304

Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 20
Study: 23595232

Group type: EXPERIMENTAL
Intervention: Olecranon memory connector (OMC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Locking plates
Number of subjects: 40
Study: 21359979

Group type: COMPARATOR
Intervention: Epinephrine injection (1/100,000) in the control group
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: No epinephrine injection in the intervention group
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 113
Study: 19583649

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Technique (PMRT) performed for 63 sessions over two months
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 66
Study: 18232619

Group type: EXPERIMENTAL
Intervention: Self-efficacy for Appropriate Medication Use Scale (SEAMS)
Number of subjects: 436
Study: 15533488

Group type: EXPERIMENTAL
Intervention: Low-fat diet (15% fat or less) with supplements (vitamin E and selenium)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low-fat diet (15% fat or less) without supplements
Number of subjects: 48

Group type: COMPARATOR
Intervention: Supplements alone (vitamin E and selenium)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 11440068

Group type: EXPERIMENTAL
Intervention: Videotaped intervention using peer educators and a health professional
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 160
Study: 9659838

Group type: EXPERIMENTAL
Intervention: E + C (ephedrine 20 mg and caffeine 200 mg)
Number of subjects: 136

Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 136
Study: 8719299

Group type: EXPERIMENTAL
Intervention: Testosterone therapy for 3 months
Number of subjects: 8

Group type: COMPARATOR
Intervention: GHRH (1 microgram/kg iv) alone
Number of subjects: 8

Group type: COMPARATOR
Intervention: GHRH combined with pyridostigmine (PD, 120 mg po)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Basal NE levels
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PD administration
Number of subjects: 8
Study: 2672909

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 12
Study: 145819

Group type: EXPERIMENTAL
Intervention: Spring-loaded clip
Number of subjects: 300

Group type: COMPARATOR
Intervention: Electrocoagulation
Number of subjects: 300
Study: 31279972

Group type: EXPERIMENTAL
Intervention: PVI + VOM ethanol infusion
Number of subjects: 405

Group type: COMPARATOR
Intervention: PVI alone
Number of subjects: 405
Study: 28067195

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) + iron
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 26031921

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg every 4 weeks up to 7 years
Number of subjects: 437
Study: 22350036

Group type: EXPERIMENTAL
Intervention: Xanthan-based 1.5% chlorhexidine (CHX) gel (Xan-CHX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 0
Study: 20924986

Group type: EXPERIMENTAL
Intervention: High goal-state access cost (mouse movement and a 2.5-s delay)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Low goal-state access cost
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Medium goal-state access cost
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Low access cost
Number of subjects: 36
Study: 19116968

Group type: EXPERIMENTAL
Intervention: Disodium EDTA administration through single needle mesotherapy and 15 minutes of pulsed-mode 1 MHz-ultrasound
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no disodium EDTA treatment)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Disodium EDTA administration
Number of subjects: 80
Study: 16924529

Group type: EXPERIMENTAL
Intervention: High intensity deep water running with vest
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study: 12692182

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (500 mg day-1 for 8 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-supplemented subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation
Number of subjects: 0
Study: 10502166

Group type: EXPERIMENTAL
Intervention: Clindamycin mouthwash
Number of subjects: 59

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 59
Study: 8709660

Group type: EXPERIMENTAL
Intervention: Insured patients
Number of subjects: 1182

Group type: COMPARATOR
Intervention: Uninsured patients
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: Discretionary services for insured patients
Number of subjects: 1182

Group type: COMPARATOR
Intervention: Discretionary services for uninsured patients
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: Nondiscretionary services for insured patients
Number of subjects: 1182

Group type: COMPARATOR
Intervention: Nondiscretionary services for uninsured patients
Number of subjects: 1182
Study: 2058825

Group type: EXPERIMENTAL
Intervention: Isoflurane‐N2O‐O2 (1.3 MAC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Total intravenous anesthesia (TIVA) with propofol and alfentanil (ED95)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Meperidine (25 mg i.v.) given to 5 patients from K1
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Shivering observed in K1
Number of subjects: 24
Study: 6641236

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 4082090

Group type: EXPERIMENTAL
Intervention: Aspirin 50 mg/day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Aspirin 324 mg/day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30500136

Group type: EXPERIMENTAL
Intervention: Plant-based hypoallergenic ointment (Doctor Rogers RESTORE® Healing Balm)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Petroleum-based lanolin-containing ointment (Aquaphor® Healing Ointment)
Number of subjects: 10
Study: 27354070

Group type: EXPERIMENTAL
Intervention: NEAT programme
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ATLAS programme
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: NEAT and ATLAS programmes
Number of subjects: 16

Group type: COMPARATOR
Intervention: Usual care control condition
Number of subjects: 16